ClinicalTrials.gg
CompletedNCT00396656Updated Jun 6, 2011Results posted

Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients

A Phase 3 interventional study of Atenolol and Hydrochlorothiazide (HCTZ)) in Hypertension, sponsored by Novartis. Completed at 2 sites in 2 countries. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-06-06.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 19 studies testing atenolol in Hypertension — none open to participants now, none under way, none of them phase 3. Atenolol · Hypertension.

Enrollment
16th of 19
30 · median 64
Started
2005
with 2 others
Phase 3
Only one
of the 19
Registered
9th of 19
by date
Lead sponsor
3 of 19
Novartis

Among the 19 studies testing atenolol in Hypertension, this one is the 16th largest by enrollment, is one of 3 that started in 2005, is the only one in phase 3, and was the 9th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 19 studies testing atenolol in Hypertension is open now. The open studies under Hypertension, anywhere →

About atenolol

Atenolol: first FDA approval 1981 (TENORMIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 40 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing atenolol in Hypertension as a file.
02

Study summary

This study evaluated the effect of valsartan on small vessel blood flow in patients with mild-to-moderate hypertension in direct comparison to atenolol and hydrochlorothiazide.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • hypertension
  • valsartan
  • atenolol
  • hydrochlorothiazide
  • microcirculation
  • arterial compliance
  • pulse wave analysis
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Caucasian; male or female outpatients and age between 40-65 years of age, inclusive.
  • At Visit 2 all patients must have a mean sitting diastolic blood pressure (msSBP) of ≥ 90 mmHg and \< 110 mmHg.

Exclusion criteria

Exclusion Criteria:

  • If a single reading for arterial hypertension in msSBP > 180 mmHg or msDBP > 110 mmHg at any visit after randomization.
  • Inability to discontinue all prior antihypertensive medications safely for a period of 2 weeks prior to randomization.
  • Known history of hypotensive symptoms or orthostatic hypotension.
  • Concomitant use of statins or statin intake during the four weeks prior to Visit 1.
  • Known Keith-Wagener grade III or IV hypertensive retinopathy.
  • A history of heart failure ( II-IV).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Valsartan followed by atenolol + hydrochlorothiazide (HCTZ)

    After a 2-week washout period, patients were treated with valsartan for 20 weeks followed by one week in which it was tapered off. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. The valsartan dose was then tapered off to 80 mg for one week. Patients took valsartan film coated tablets orally once a day (od) in the morning. After a second 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning.

    Drug: Atenolol · Drug: Hydrochlorothiazide (HCTZ)) · Drug: Valsartan

  • Experimental
    Atenolol + hydrochlorothiazide (HCTZ) followed by valsartan

    After a 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks followed by one week in which atenolol was tapered off and HCTZ was discontinued. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning. After a second 2-week washout period, patients were treated with valsartan for 20 weeks. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. Patients took valsartan film coated tablets orally once a day (od) in the morning.

    Drug: Atenolol · Drug: Hydrochlorothiazide (HCTZ)) · Drug: Valsartan

Interventions

06

What researchers measure

Primary outcomes

  1. Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Injected Sites Compared to NaCl Injected Sites

    10 µl of acetylcholine (ACH) at 3 concentrations (10-7, 10-8, 10-9 M) was injected intra-dermally at 3 sites on the forearms. NaCl was injected at 2 sites on the forearms. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. Means for the 3 ACH and the 2 NaCl sites were calculated and compared. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner.

    Time frame: At end of each treatment period (Week 21 and Week 43)

Secondary outcomes

  1. Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Plus L-NMMA Injected Sites Compared to NaCl Injected Sites

    10 µl of acetylcholine (ACH) at 3 concentrations (10-7, 10-8, 10-9 M) plus 10 µl L-NMMA (10-6 M) was injected intra-dermally at 3 sites on the forearms. NaCl was injected at 2 sites. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. Means for the 3 ACH and the 2 NaCl sites were calculated and compared. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner.

    Time frame: At end of each treatment period (Week 21 and Week 43)

  2. Difference in Mean Post-treatment Microcirculation at a Sodium Nitroprusside Injected Site Compared to NaCl Injected Sites

    10 µl of sodium nitroprusside at a concentration of 10-7 M was injected intra-dermally at 1 site on the forearms. NaCl was injected at 2 sites on the forearms. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. A mean for the 2 NaCl sites was calculated and compared to the sodium nitroprusside mean. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner.

    Time frame: At end of each treatment period (Week 21 and Week 43)

  3. Mean Post-treatment Microcirculation at NaCl Injected Sites

    10 µl of NaCl was injected intra-dermally at 2 sites on the forearms. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. A mean for the 2 NaCl sites was calculated. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner.

    Time frame: At end of each treatment period (Week 21 and Week 43)

  4. Arterial Pressure Waveform Augmentation Index at the End of Treatment

    Using applanation tonometry, the arterial pulse form measured at the wrist was analyzed using computerized pulse wave analysis. The arterial pressure waveform has two components; the first is the forward traveling wave when the left ventricle contracts and the second is the reflected wave returning from the periphery. The augmentation index is the ratio of the first and second systolic peaks and is used as a surrogate measure of arterial stiffness.

    Time frame: At end of each treatment period (Week 21 and Week 43)

  5. Arterial Pressure Waveform Pulse Wave Velocity at the End of Treatment

    Using applanation tonometry, the arterial pulse form measured at the wrist was analyzed using computerized pulse wave analysis. The arterial pressure waveform has two components; the first is the forward traveling wave when the left ventricle contracts and the second is the reflected wave returning from the periphery. Pulse wave velocity is the speed of the forward traveling wave and can be used as a measure of arterial stiffness since the more rigid the wall of the artery, the faster the wave moves.

    Time frame: At end of each treatment period (Week 21 and Week 43)

07

Results

Posted Jun 6, 2011

Participant flow

First Treatment Period
Participant flow — First Treatment Period
MilestoneValsartan Followed by Atenolol + Hydrochlorothiazide (HCTZ)Atenolol + Hydrochlorothiazide (HCTZ) Followed by Valsartan
Started1515
Completed1513
Not completed02
Withdrew: Withdrawal by subject02
Second Treatment Period
Participant flow — Second Treatment Period
MilestoneValsartan Followed by Atenolol + Hydrochlorothiazide (HCTZ)Atenolol + Hydrochlorothiazide (HCTZ) Followed by Valsartan
Started1513
Completed1512
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimaryDifference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Injected Sites Compared to NaCl Injected Sites

10 µl of acetylcholine (ACH) at 3 concentrations (10-7, 10-8, 10-9 M) was injected intra-dermally at 3 sites on the forearms. NaCl was injected at 2 sites on the forearms. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. Means for the 3 ACH and the 2 NaCl sites were calculated and compared. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner.

Time frame:
At end of each treatment period (Week 21 and Week 43)
Reported as:
Mean · Perfusion units
Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Injected Sites Compared to NaCl Injected Sites
Perfusion unitsValsartanAtenolol + Hydrochlorothiazide
Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Injected Sites Compared to NaCl Injected Sites61.21 ± 38.1161.04 ± 49.16
SecondaryDifference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Plus L-NMMA Injected Sites Compared to NaCl Injected Sites

10 µl of acetylcholine (ACH) at 3 concentrations (10-7, 10-8, 10-9 M) plus 10 µl L-NMMA (10-6 M) was injected intra-dermally at 3 sites on the forearms. NaCl was injected at 2 sites. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. Means for the 3 ACH and the 2 NaCl sites were calculated and compared. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner.

Time frame:
At end of each treatment period (Week 21 and Week 43)
Reported as:
Mean · Perfusion units
Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Plus L-NMMA Injected Sites Compared to NaCl Injected Sites
Perfusion unitsValsartanAtenolol + Hydrochlorothiazide
Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Plus L-NMMA Injected Sites Compared to NaCl Injected Sites-9.11 ± 22.19-5.60 ± 40.47
SecondaryDifference in Mean Post-treatment Microcirculation at a Sodium Nitroprusside Injected Site Compared to NaCl Injected Sites

10 µl of sodium nitroprusside at a concentration of 10-7 M was injected intra-dermally at 1 site on the forearms. NaCl was injected at 2 sites on the forearms. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. A mean for the 2 NaCl sites was calculated and compared to the sodium nitroprusside mean. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner.

Time frame:
At end of each treatment period (Week 21 and Week 43)
Reported as:
Mean · Perfusion units
Difference in Mean Post-treatment Microcirculation at a Sodium Nitroprusside Injected Site Compared to NaCl Injected Sites
Perfusion unitsValsartanAtenolol + Hydrochlorothiazide
Difference in Mean Post-treatment Microcirculation at a Sodium Nitroprusside Injected Site Compared to NaCl Injected Sites120.65 ± 74.52128.14 ± 63.79
SecondaryMean Post-treatment Microcirculation at NaCl Injected Sites

10 µl of NaCl was injected intra-dermally at 2 sites on the forearms. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. A mean for the 2 NaCl sites was calculated. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner.

Time frame:
At end of each treatment period (Week 21 and Week 43)
Reported as:
Mean · Perfusion units
Mean Post-treatment Microcirculation at NaCl Injected Sites
Perfusion unitsValsartanAtenolol + Hydrochlorothiazide
Mean Post-treatment Microcirculation at NaCl Injected Sites44.78 ± 47.5350.96 ± 67.88
SecondaryArterial Pressure Waveform Augmentation Index at the End of Treatment

Using applanation tonometry, the arterial pulse form measured at the wrist was analyzed using computerized pulse wave analysis. The arterial pressure waveform has two components; the first is the forward traveling wave when the left ventricle contracts and the second is the reflected wave returning from the periphery. The augmentation index is the ratio of the first and second systolic peaks and is used as a surrogate measure of arterial stiffness.

Time frame:
At end of each treatment period (Week 21 and Week 43)
Reported as:
Mean · Ratio
Arterial Pressure Waveform Augmentation Index at the End of Treatment
RatioValsartanAtenolol + Hydrochlorothiazide
Arterial Pressure Waveform Augmentation Index at the End of Treatment139.05 ± 20.64144.51 ± 21.97
SecondaryArterial Pressure Waveform Pulse Wave Velocity at the End of Treatment

Using applanation tonometry, the arterial pulse form measured at the wrist was analyzed using computerized pulse wave analysis. The arterial pressure waveform has two components; the first is the forward traveling wave when the left ventricle contracts and the second is the reflected wave returning from the periphery. Pulse wave velocity is the speed of the forward traveling wave and can be used as a measure of arterial stiffness since the more rigid the wall of the artery, the faster the wave moves.

Time frame:
At end of each treatment period (Week 21 and Week 43)
Reported as:
Mean · Meters per second
Arterial Pressure Waveform Pulse Wave Velocity at the End of Treatment
Meters per secondValsartanAtenolol + Hydrochlorothiazide
Arterial Pressure Waveform Pulse Wave Velocity at the End of Treatment8.07 ± 1.287.60 ± 1.18

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valsartan—0/28 (0%)16/28 (57.1%)
Atenolol + Hydrochlorothiazide—1/30 (3.3%)12/30 (40%)
Most frequent serious events
Most frequent serious events
EventValsartanAtenolol + Hydrochlorothiazide
DiverticulitisInfections and infestations0/281/30
Most frequent other events
Showing 10 of 13
Most frequent other events
EventValsartanAtenolol + Hydrochlorothiazide
HeadacheNervous system disorders3/286/30
VertigoEar and labyrinth disorders3/282/30
BronchitisInfections and infestations2/281/30
CystitisInfections and infestations2/281/30
SinusitisInfections and infestations2/281/30
Upper respiratory tract infectionInfections and infestations2/281/30
Musculoskeletal painMusculoskeletal and connective tissue disorders2/280/30
HypotensionVascular disorders2/280/30
DiarrhoeaGastrointestinal disorders1/282/30
Chest painGeneral disorders0/282/30

Baseline characteristics

Age Continuous
Age Continuous(years)Entire Study Population
Mean52.3 ± 7.2
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female11
Male19
08

Study locations

2 sites
  • Investigative Centers, Germany
  • Novartis Pharma Ag
    Basel, Switzerland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2006
First posted
Nov 7, 2006
Start
Dec 2005
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Results first posted
Jun 6, 2011
Last update
Jun 6, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00396656
Lead sponsor
Novartis
First posted
Nov 7, 2006
Start date
Dec 2005
Primary completion
Dec 2007
Completion
Dec 2007
Results posted
Jun 6, 2011
Last update
Jun 6, 2011

Study contacts

Novartis Pharma Ag
principal investigator · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atenolol · Hydrochlorothiazide · Valsartan

Start the discussion